Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP 18 and the degradation ofGLP-1.
Concurrent therapy with a DPP-4 inhibitor and a glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended. When selecting a treatment regimen, consider factors such as cardiovascular and renal comorbidities, drug efficacy and adverse effects, hypoglycemic risk, presence of overweight and obesity, cost, access, and patient preferences.
GLP-1receptor agonists andGLP-1and glucose-dependent insulinotropic peptide agonists have several mechanisms of action, including reduction of gastric emptying, inhibition of glucagon secretion ...
12.1 Mechanism of Action - Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the ...
Saxagliptininhibits dipeptidyl peptidase IV (DPP-IV) enzyme resulting in prolonged active incretin levels. It elevates the circulating levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) which stimulates insulin secretion in pancreatic β-cells in a glucose dependent manner. It improves glycaemic control by reducing fasting and postprandial plasma ...
Drug TargetSaxagliptinis an orally active, antidiabetic drug that works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4) (Augeri et al., 2005). In response to food intake, endocrine cells in the gastrointestinal tract release incretin hormones,GLP-1and GIP, to stimulate insulin secretion.
